First patient expected to be dosed in the DUET study in the fourth quarter of 2026Milestone triggers second closing of March 2025 private ...
The latest installment in BioPharma Dive’s data visualization series features a closer look at Kodiak’s stock performance and ...
Key Takeaways VOYAGER real-world data showed visual and anatomical improvements with Vabysmo in treatment-naive eyes across ...
The Icahn School of Medicine at Mount Sinai has named Napoleone Ferrara, MD, Distinguished Professor of Pathology and ...
Three studies presented at the 26th EURETINA Congress, taking place at the VIECON – Vienna Congress & Convention Center from ...
It has been a remarkable journey for Kodiak Sciences Inc. , whose share price has nearly tripled in just one month, climbing ...
ISELIN - Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA (bevacizumab-vikg, bevacizumab gamma) for the treatment of ...
Fintel on MSN
Argus Research upgrades Regeneron Pharmaceuticals, Inc. - Depositary Receipt to buy from hold
Fintel reports that on October 1, 2026, Argus Research upgraded their outlook for Regeneron Pharmaceuticals, Inc. - Depositary Receipt (BOVESPA:REGN34) from Hold to Buy. Regeneron Pharmaceuticals, Inc ...
OCUL stock selloff began on Monday after Kodiak Sciences and 4D Molecular posted updates from clinical trials of their ...
Ester Carreño, MD, PhD, explains how to tell retinitis pigmentosa from uveitis and why genetic confirmation now matters more.
ASHLAND, KY / ACCESS Newswire / October 1, 2026 / Serving patients of all age groups, Weber West Eye Care has been providing eye care to the tri-state area for more than 10 years. The practice has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results